Does Rallies show 13F holders for CAMP?

Yes. Rallies tracks hedge fund and 13F ownership data for CAMP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CAMP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CAMP. It does not provide personalized investment advice.

CAMP (CAMP4 Therapeutics Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

CAMP4 Therapeutics Corporation Common Stock (CAMP) is a publicly traded Healthcare sector company. As of May 21, 2026, CAMP trades at $4.50 with a market cap of $236.78M and a P/E ratio of -1.90. CAMP moved +8.80% today. Year to date, CAMP is -24.87%; over the trailing twelve months it is +101.79%. Its 52-week range spans $1.31 to $12.30. Analyst consensus is strong buy with an average price target of $8.60. Rallies surfaces CAMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CAMP stock?

Hedge funds tracked by Rallies that own CAMP include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CAMP4 Therapeutics Corporation Common Stock.

CAMP Key Metrics

Key financial metrics for CAMP
Metric	Value
Price	$4.50
Market Cap	$236.78M
P/E Ratio	-1.90
EPS	$-2.36
Dividend Yield	0.00%
52-Week High	$12.30
52-Week Low	$1.31
Volume	0
Avg Volume	0
Revenue (TTM)	$3.93M
Net Income	$-86.30M
Gross Margin	0.00%

Top Hedge Funds Holding CAMP

Exoduspoint Capital holds 34.72K shares of CAMP, changed +0.00% as of Dec 31, 2025.

Latest CAMP News

CAMP4 Therapeutics’ CMP-002 Increases Seizure Threshold, Reduces Severity in SYNGAP1 Model — May 14, 2026
CAMP4 Secures EMA Orphan Designation, Files CMP-002 Trial in Australia, $99M Cash Runway — May 7, 2026
CAMP4 Therapeutics Maps Thousands of Regulatory RNAs, Increases OTC Expression — Apr 28, 2026
CAMP4 Raises $97.5M, Wins $17.5M GSK Upfront, Plans H2 2026 Phase 1/2 for CMP-002 — Mar 5, 2026
CAMP4 Grants 8,000 Options at $3.85 Exercise Price with Four-Year Vesting — Feb 20, 2026

Recent CAMP Insider Trades

5AM Partners VI, LLC bought 2.94M (~$4.50M) on Sep 11, 2025.
Polaris Management Co. VII, L.L.C. bought 1.22M (~$1.87M) on Sep 11, 2025.
Polaris Management Co. VII, L.L.C. bought 85.47K (~$130.77K) on Sep 11, 2025.

CAMP Analyst Consensus

6 analysts cover CAMP: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.60.

Common questions about CAMP

Who owns CAMP stock?: Hedge funds tracked by Rallies that own CAMP include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CAMP4 Therapeutics Corporation Common Stock.
Does Rallies show 13F holders for CAMP?: Yes. Rallies tracks hedge fund and 13F ownership data for CAMP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CAMP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CAMP. It does not provide personalized investment advice.